is there an fda approved oral glp 1 In a major milestone for obesity care, the has Wegovy® as the first GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight and related conditions FDA UPDATE: A new oral
Description
Semaglutide is not indicated for type 1 diabetes
Pechenov, S

Practical considerations such as injection frequency, needle size, and gastrointestinal tolerability may also influence individual patient selection

But the bigger question, in his view, is access
